Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort

Sheu, Ming Jen; Liang, Fu-Wen; Lu, Tsung Hsueh

doi:10.1111/jvh.13436

Cited by 5 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These medications were introduced in Brazil in 2013, and, since then, the Brazilian Ministry of Health has updated its clinical protocol and therapeutic guidelines with the inclusion of new medications and expanded access to treatment, which, since 2017, has included all diagnosed cases of chronic hepatitis C in Brazilian territory [ 34 ]. It is important to note that the present study only considered those whose underlying cause of death was acute (B 17.1) or chronic (B 18.2) hepatitis C. Therefore, the causes of death recorded as a complication or aggravation associated with HCV, such as liver cirrhosis or liver cancer, may cause an underestimation of the HCV mortality rate found here [ 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018

et al. 2022

View full text Add to dashboard Cite

Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030. In Brazil, efforts have been undertaken to achieve this goal; there are, however, great challenges. It is important to understand the disease profile in different regions of the country in order to design strategies to fight the disease nationwide. The objective of this study was to analyse the time trend of the incidence and mortality of hepatitis C in Brazil during the period from 2008 to 2018 according to sociodemographic and clinical characteristics. Methods All newly diagnosed cases of hepatitis C reported between 2008 and 2018, in all regions of Brazil, were included. The indicators were obtained from the databases of the Brazilian Ministry of Health. For the time series analysis, a joinpoint regression model was used. Results Between 2008 and 2018, 136,759 newly diagnosed cases of hepatitis C were reported considering anti-HCV and HCV RNA positivity, and 271,624 newly diagnosed cases were reported considering one or another positive test. The majority of the records were concentrated in the Southeast (61%) and South (26.2%) Regions. The joinpoint regression model indicated an increasing trend in the detection rate of hepatitis C in Brazil, but there was a decreasing trend in the mortality rate during the period analysed. Conclusions Differences were observed in the time trend of hepatitis C and in the sociodemographic and clinical characteristics in different regions of Brazil. These data can provide support to design strategies for the elimination of hepatitis C in Brazil, according to regional particularities.

show abstract

Section: Discussionmentioning

confidence: 99%

A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The findings of this national population-based study indicate that a persistent decline in the cryoglobulinemia mortality rates from 1999 to 2010, followed by a mild increase from 2010 to 2014, and then an abrupt decline from 2014 to 2018. The study has indicated high prevalence of HCV among baby boomers born 1945–1964 and resulted in the increase of HCV mortality since 2000 [ 13 , 14 ]. The cryoglobulinemia mortality for middle-age adults aged 55–64 years increased since early 2000s (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…1 C) and for older adults aged ≥ 65 years increased since 2010 (Fig. 1 D) corresponding to age-specific HCV mortality rates of baby boomers born 1950–1959 and 1945–194, respectively [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…The abrupt decline in cryoglobulinemia mortality since 2014 among decedents aged 55–64 years and ≥ 65 years can be mainly attributed to the introduction of DAAs in 2014. However, the magnitude of the decline was more prominent among decedents aged 55–64 years (APC was − 14.3%) than among decedents aged ≥ 65 years (APC was − 14.3%), which might be due to different access to DAA among two sub-cohort baby boomers [ 14 ]. The proportion of patients with cryoglobulinemia and HCV reported in a French study was 63% in 2011, 60% in 2015, and 33% in 2018 [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals

et al. 2022

View full text Add to dashboard Cite

Background Hepatitis C virus (HCV) is the main etiology of cryoglobulinemia with mortality around 25%. Little is known on the changes in cryoglobulinemia mortality after the introduction of direct-acting antivirals (DAA) for treatment of HCV in 2014 in the USA. Methods We used the multiple-cause mortality files compiled by the National Center for Health Statistics to calculate cryoglobulinemia mortality from 1999 to 2018. The proportionate mortality ratio (PMR) of cryoglobulinemia cases with HCV and those with autoimmune diseases was computed to assess the impact of introduction of DAA. Results We identified 1299 people aged ≥ 20 years who died with cryoglobulinemia between 1999 and 2018. The cryoglobulinemia mortality (deaths per million) declined from 1999 (0.4) to 2010 (0.22) and mildly increased to 2014 (0.26), and then decreased abruptly from 2014 to 2018 (0.19) with annual percent change of − 14.3%. The proportion of cryoglobulinemia patients with HCV was 39% (118/302) in 2009–2013 and 26% (81/310) in 2014–2018, with a PMR of 0.67 (95% CI 0.50–0.89). By contrast, the proportion of cryoglobulinemia patients with systemic autoimmune diseases was 2.6% (8/302) in 2009–2013 and 4.2% (13/310) in 2014–2018, with a PMR of 1.58 (95% CI 0.66–3.82). Conclusion The changes in cryoglobulinemia mortality during the past two decades are mainly related to the aging and dying of the “baby boomer” cohort who had a high HCV prevalence and to the introduction of a DAA in 2014.

show abstract

“…The age-speci c cryoglobulinemia mortality trend patterns correspond with the age-speci c HCV mortality trend patterns. 13 The age differences in mortality trend patterns re ect the aging and dying of "baby boomers" (born between 1945 and 1965 in the United States) with a high prevalence of HCV. 14 The increased cryoglobulinemia mortality among middle-age adults aged 55-64-years from the early 2000s and older adults aged 65-years and above from the late 2000s can be mainly attributed to the aging of "baby boomers.…”

Section: Discussionmentioning

confidence: 99%

Secular trends in cryoglobulinemia mortality in the United States in the era of direct-acting antivirals

Guo

Gao

Duan

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background Hepatitis C virus (HCV) is the main etiology of cryoglobulinemia with mortality around 25%. Little is known on the changes in cryoglobulinemia mortality after the introduction of direct-acting antivirals (DAA) for treatment of HCV in 2014 in the US. Methods We calculated cryoglobulinemia mortality from 1999 to 2018. The proportionate mortality ratio (PMR) of cryoglobulinemia cases with HCV and those with autoimmune diseases were computed to assess the impact of introduction of DAA. Results We identified 1299 people aged ≥ 20 years who died with cryoglobulinemia between 1999 and 2018. The cryoglobulinemia mortality (deaths per million) declined from 1999 (0.4) to 2010 (0.22) and mildly increased from 2010 to 2014 (0.26), and then decreased abruptly from 2014 to 2018 (0.19). The proportion of cryoglobulinemia patients with HCV was 39% (118/302) in 2009–2013 and 26% (81/310) in 2014–2018, with a PMR of 0.67 (95% CI 0.50–0.89). By contrast, the proportion of cryoglobulinemia patients with systemic autoimmune diseases was 2.6% (8/302) in 2009–2013 and 4.2% (13/310) in 2014–2018, with a PMR of 1.58 (95% CI 0.66–3.82). Conclusion The changes in cryoglobulinemia mortality during the past two decades are mainly related to the aging and dying of the “baby boomer” cohort who had a high HCV prevalence and to the introduction of a DAA in 2014.

show abstract

Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort

Cited by 5 publications

References 20 publications

A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018

A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018

Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals

Secular trends in cryoglobulinemia mortality in the United States in the era of direct-acting antivirals

Contact Info

Product

Resources

About